Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Ivonescimab + Pemetrexed Disodium |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Ivonescimab | AK112|AK 112|AK-112|SMT112|SMT 112|SMT-112 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 VEGFA Antibody 4 | Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227). | |
Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05184712 | Phase III | Carboplatin + Pemetrexed Disodium Ivonescimab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Ivonescimab + Pemetrexed Disodium | Phase 3 Clinical Study of AK112 for NSCLC Patients | Active, not recruiting | 1 |